StreetInsider.com News Articles

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

Thu, 15 Oct 2026 16:01:00 -0400

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj^® (revumenib), the Company’s first-in-class menin inhibitor, has been selected by TIME as one of the “Best Inventions of 2026” in the Medical and Healthcare category.

TIME’s annual list of the Best Inventions features 300 extraordinary inventions changing lives. To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields—such as healthcare and AI. TIME

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

Thu, 15 Oct 2026 16:01:00 -0400

Stifel Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

Tue, 13 Oct 2026 09:44:55 -0400

Stifel analyst Stephen Willey reiterated a Buy rating and $40.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).

The analyst commented, "Following today’s (October 12, 2026) market close, SNDX announced the P2 MAXPIRe trial evaluating axatilimab in IPF patients did not meet the primary endpoint of annualized rate of FVC decline (vs. placebo) at Week 26 – with management appropriately now abandoning future axatilimab development efforts in IPF. We candidly shared management’s enthusiasm for axatilimab’s mechanistic translation here following previously-reported activity in a severe, lung-manifesting subgroup of patients with BOS-associated GVHD – but MAXPIRe unfortunately now replicates the clinical attrition historically characterizing

Syndax Pharmaceuticals (SNDX) call put ratio 1 call 1.3 puts into share price lower before the bell

Tue, 13 Oct 2026 05:35:30 -0400

Syndax Pharmaceuticals (NASDAQ: SNDX) 30-day option implied volatility is at 101; compared to its 52-week range of 53 to 120. Call put ratio 1 call 1.3 puts into share price lower before the bell.

Citi reiterates Buy rating on Syndax Pharmaceuticals after stock drop

Tue, 13 Oct 2026 05:03:39 -0400

Citi analyst Yigal Nochomovitz reiterated a Buy rating and $57.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).

The reiteration follows an approximately 15% decline in the stock after axatilimab's Phase 2 MAXPIRe trial missed its endpoint in idiopathic pulmonary fibrosis (IPF).

Nochomovitz stated that IPF had not been included in Citi's valuation, describing it as "upside optionality," and said the trial outcome "does not meaningfully alter our core thesis." The analyst added that study conduct and safety were "good/clean," which he said limits concern about any readthrough to chronic graft-versus-host disease (cGVHD).

The analyst described the company's decision to discontinue IPF development as

Citi reiterates Buy rating on Syndax Pharmaceuticals after stock drop

Tue, 13 Oct 2026 05:03:39 -0400

Citi analyst Yigal Nochomovitz reiterated a Buy rating and $57.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).

The reiteration follows an approximately 15% decline in the stock after axatilimab's Phase 2 MAXPIRe trial missed its endpoint in idiopathic pulmonary fibrosis (IPF).

The analyst described the company's decision to discontinue IPF development as

Syndax Pharmaceuticals stock tumbles on failed IPF trial

Mon, 12 Oct 2026 16:12:16 -0400

Investing.com -- Syndax Pharmaceuticals (NASDAQ:SNDX) shares fell 15% after-hours Monday following the company’s announcement that its axatilimab drug failed to meet the primary endpoint in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF).

The MAXPIRe trial did not achieve its primary endpoint of the annualized rate of decline in forced vital capacity (FVC), the company said. Based on these results, Syndax does not plan to pursue further development of axatilimab in IPF.

The trial enrolled 145 patients across 62 sites in 14 countries. Patients were randomized 2:1 to receive axatilimab 0.3 mg/kg or placebo every two weeks

Syndax Pharmaceuticals stock tumbles on failed IPF trial

Mon, 12 Oct 2026 16:12:16 -0400

The trial enrolled 145 patients across 62 sites in 14 countries. Patients were randomized 2:1 to receive axatilimab 0.3 mg/kg or placebo every two weeks

Syndax's axatilimab fails IPF trial's primary endpoint

Mon, 12 Oct 2026 16:01:14 -0400

Syndax Pharmaceuticals (Nasdaq: SNDX) announced that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualized rate of decline in forced vital capacity (FVC).

The trial was a 26-week, randomized, double-blind, placebo-controlled, multicenter study enrolling 145 patients across 62 sites in 14 countries. Patients were randomized 2:1 to receive axatilimab 0.3 mg/kg or placebo every two weeks. Based on the results, Syndax said it does not plan to pursue further development of axatilimab in IPF.

Axatilimab was reported to be well tolerated in the trial, with a safety profile comparable to

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

Mon, 12 Oct 2026 16:01:00 -0400

– Trial did not meet the primary endpoint of annualized rate of FVC decline –

– Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed –

– Axatilimab continues to advance in multiple trials in cGVHD with results expected later this year and early 2028 –

NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualized rate

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

Mon, 12 Oct 2026 16:01:00 -0400

– Trial did not meet the primary endpoint of annualized rate of FVC decline –

– Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed –

– Axatilimab continues to advance in multiple trials in cGVHD with results expected later this year and early 2028 –

H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

Mon, 12 Oct 2026 06:53:16 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $38.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).

The analyst commented: "The Street has not forgotten the long history of failures in IPF, and we believe that skepticism under-appreciates Niktimvo’s (axatilimab) potential heading into the 4Q26 MAXPIRe readout. We are constructive on the readout given the role of CSF-1R-dependent macrophages in lung fibrosis and Niktimvo’s demonstrated pulmonary benefits in cGVHD-related bronchiolitis obliterans syndrome. These findings provide a credible human clinical signal alongside the mechanistic rationale, with responses emerging early enough to support a measurable treatment effect within MAXPIRe’s 26-week window. Our

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2026, the Company granted inducement awards to purchase up to 213,300 shares of common stock to nine new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

Thu, 01 Oct 2026 06:56:44 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $38.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).

The analyst commented: "Ahead of 3Q earnings, we completed a deeper diligence effort around NPM1m AML biology and market dynamics that provides a granular understanding of the unique headwinds and underappreciated opportunities within R/R NPM1m AML. Our work centered on revisiting commercial assumptions for the NPM1m AML market as compared to KMT2Ar. We spoke to leading hematologist-oncologists to gain a quick perspective on how targeted therapies like Revuforj are being integrated into existing treatment algorithms, and how those protocols diverge between different genetic

Jefferies Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

Tue, 29 Sep 2026 06:37:15 -0400

Jefferies analyst Faisal Khurshid reiterated a Buy rating and $35.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).

The analyst comments "SNDX will report Ph2 MAXPIRe data for axatilimab (anti-CSF-1R) in IPF in 4Q. We want to see >30mL pbo-adj FVC benefit at Wk26 to have confidence in the go-forward pot'l, and our analysis suggests ~55% chance to clear the bar. Our deep dive includes a robust analysis of the macrophage targeting hypothesis in IPF, which we see as reasonable. We see this as an attractive call option w/ >50% upside, and pot'l to broaden the story beyond AML. See slides within.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 16:01:00 -0400

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 16:01:00 -0400

Syndax Announces Participation in September Investor Conferences

Tue, 01 Sep 2026 07:00:00 -0400

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

Citi 2026 Biopharma Back to School Conference in New York, NY with a fireside chat on Thursday, September 10, 2026, at 8:40 a.m. ET.
H.C. Wainwright 28th Annual Global Investment Conference in New York, NY with a fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET.
Syndax Announces Participation in September Investor Conferences

Tue, 01 Sep 2026 07:00:00 -0400

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
- Citi 2026 Biopharma Back to School Conference in New York, NY with a fireside chat on Thursday, September 10, 2026, at 8:40 a.m. ET.
- H.C. Wainwright 28th Annual Global Investment Conference in New York, NY with a fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET.
  
  Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at UBS as Revuforj New Starts Decline
  
  Fri, 21 Aug 2026 07:39:18 -0400
  
  UBS analyst David Dai lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $33.00 (from $37.00) while maintaining a Buy rating.
  The analyst commented, "In 2Q26, while new Revuforj patient starts decline to ~250 (vs. ~330 in 1Q), maintenance patients increased to ~169 in 2Q (vs. ~44 in 1Q) based on our estimates. We view the increased maintenance patients as encouraging. Based on discussion with mgmt, we expect new patient starts to recover in 2H and we estimate ~330 in 3Q26 and ~413 in 4Q26, including ~132/~161 NPM1m and ~198/~253 KMT2Ar patients, respectively. Together with increasing post-HSCT maintenance use, we estimate Revuforj
  
  Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at UBS as Revuforj New Starts Decline
  
  Fri, 21 Aug 2026 07:39:18 -0400
  
  UBS analyst David Dai lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $33.00 (from $37.00) while maintaining a Buy rating.
  The analyst commented, "In 2Q26, while new Revuforj patient starts decline to ~250 (vs. ~330 in 1Q), maintenance patients increased to ~169 in 2Q (vs. ~44 in 1Q) based on our estimates. We view the increased maintenance patients as encouraging. Based on discussion with mgmt, we expect new patient starts to recover in 2H and we estimate ~330 in 3Q26 and ~413 in 4Q26, including ~132/~161 NPM1m and ~198/~253 KMT2Ar patients, respectively. Together with increasing post-HSCT maintenance use, we estimate Revuforj
  
  Syndax Pharmaceuticals (SNDX) PT Lowered to $40 at JPMorgan
  
  Tue, 11 Aug 2026 08:49:28 -0400
  JPMorgan analyst Anupam Rama lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $40.00 (from $44.00) while maintaining a Overweight rating.
  
  Form SCHEDULE 13G Syndax Pharmaceuticals Filed by: STATE STREET CORP
  
  Fri, 07 Aug 2026 11:00:00 -0400
  si-local-file:///var/storage/secattach/20260807/26889223.html
  
  Form SCHEDULE 13G Syndax Pharmaceuticals Filed by: STATE STREET CORP
  
  Fri, 07 Aug 2026 11:00:00 -0400
  si-local-file:///var/storage/secattach/20260807/26889223.html

StreetInsider.com News Articles

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

Stifel Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals (SNDX) call put ratio 1 call 1.3 puts into share price lower before the bell

Citi reiterates Buy rating on Syndax Pharmaceuticals after stock drop

Citi reiterates Buy rating on Syndax Pharmaceuticals after stock drop

Syndax Pharmaceuticals stock tumbles on failed IPF trial

Syndax Pharmaceuticals stock tumbles on failed IPF trial

Syndax's axatilimab fails IPF trial's primary endpoint

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

Jefferies Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Participation in September Investor Conferences

Syndax Announces Participation in September Investor Conferences

Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at UBS as Revuforj New Starts Decline

Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at UBS as Revuforj New Starts Decline

Syndax Pharmaceuticals (SNDX) PT Lowered to $40 at JPMorgan

Form SCHEDULE 13G Syndax Pharmaceuticals Filed by: STATE STREET CORP

Form SCHEDULE 13G Syndax Pharmaceuticals Filed by: STATE STREET CORP